PHP
ALLK

Parkman Healthcare Partners’s Allakos ALLK Stock Holding History

Parkman Healthcare Partners’s Portfolio ALLK Stock Details ALLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-160,376
Closed -$502K – 90
2022
Q2 		$502K Buy
160,376
+8,310
+5% +$31.1K 0.18% 69
2022
Q1 		$867K Buy
+152,066
New +$983K 0.25% 70

Other funds holding ALLK

LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Parkman Healthcare Partners's ALLK Position: Q3 2022 in Review

Parkman Healthcare Partners sold out of Allakos (ALLK) in Q3 2022, closing a stake of 160,376 shares — an estimated $502K sold.

Parkman Healthcare Partners first reported a position in ALLK in Q1 2022 and held it in 2 quarters. The position peaked at $867K in Q1 2022. 105 funds tracked by Wall St. Rank hold ALLK as of Q3 2022.

  • Parkman Healthcare Partners reported no remaining Allakos position as of Q3 2022 after selling out during the quarter.
  • Parkman Healthcare Partners sold 160,376 Allakos shares in Q3 2022, an estimated $502K.
  • Parkman Healthcare Partners first reported a position in Allakos in Q1 2022 and held it in 2 quarters.
  • Parkman Healthcare Partners's Allakos position peaked at $867K in Q1 2022.
  • 105 funds tracked by Wall St. Rank held Allakos as of Q3 2022.

Based on Parkman Healthcare Partners's 13F filing for Q3 2022, filed 14 Nov 2022.